Phase I/II Trial GOFL in Advanced Pancreatic Adenocarcinoma
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
We plan to conduct a phase I/II clinical trial using biweekly gemcitabine, oxaliplatin, and
48-hour infusion of high dose 5-FU/leucovorin to treat patients with advanced pancreatic
adenocarcinoma. In the phase I part, the maximum tolerable dose of oxaliplatin in combination
with biweekly gemcitabine 800 mg/m2 and 48-hour infusion of 5-FU 3000 mg/m2 and leucovorin
300 mg/m2 will be determined. In the phase II part, the efficacy and safety of the biweekly
chemotherapy with GOFL will be evaluated.